Health

Pancreatic cancer study finds biological differences in tumors across racial backgrounds

Researchers at the University of Cincinnati identified cellular and immune variations in pancreatic tumors from Black and non-African American patients, which could help advance personalized cancer care.

A gloved hand operating a microscope in a laboratory
Akram Huseyn / Unsplash, Unsplash License

CINCINNATI — Researchers at the University of Cincinnati have identified biological differences in pancreatic cancer tumors among patients of different racial backgrounds, offering potential clues into why the disease impacts populations differently and opening new avenues for personalized treatment.

The study, published in the journal Cancer Research, analyzed 22 pancreatic tumors collected from patients across the country, comprising seven Black patients alongside 15 non-African American individuals. Led by Nina Steele, an assistant professor in the University of Cincinnati College of Medicine, the research team examined both cancer cells and surrounding immune responses.

Key Cellular and Immune Variations

According to the findings, pancreatic tumors from Black patients contained fewer standard pancreatic cancer cells and a higher proportion of cells exhibiting mixed characteristics. Researchers noted that some of these intermediate cell traits have been linked to drug resistance, though the study did not demonstrate whether the variations directly influenced treatment outcomes.

The investigation also revealed distinct immune system differences. Tumors from Black patients showed higher concentrations of B cells, a type of immune cell, as well as larger overall immune cell clusters. Steele’s team observed signs suggesting that certain B cells might suppress the body’s natural defense against cancer, although the broader significance of these differences remains under study.

Despite these differences in cell behavior and immune architecture, the study found no significant disparities between the patient groups regarding the primary genetic mutations known to drive pancreatic cancer growth.

Data cited by the researchers indicates that Black Americans face about a 20 percent higher likelihood of developing pancreatic cancer compared to non-African Americans. Steele emphasized that previous scientific literature lacked an accurate representation of the diverse demographics affected by the disease.

“This study shows that ignoring diverse ancestry in medical research leaves blind spots in the search for a cure,” Steele told Fox News Digital, adding that medical systems must ensure clinical trials reflect all populations at risk.

Expert Perspective and Study Limitations

Dr. Raymond Wadlow, a gastrointestinal medical oncologist at the Inova Schar Cancer Institute in Virginia who was not involved in the research, noted that utilizing the immune system to combat pancreatic cancer has long proven difficult. He explained that pancreatic tumors often hijack immune cells, causing them to support tumor growth rather than defend the host.

Wadlow told Fox News Digital that while pancreatic cancers can share fundamental DNA mutations, the behavior of individual cells and their interactions with nearby tissue can vary widely across patient populations. He stressed, however, that the initial findings remain “a long way from changing patient care.”

Wadlow also emphasized that race and genetic ancestry do not account for environmental, social and biological factors that could influence tumor development. He recommended that newly diagnosed patients ask about hereditary genetic testing to determine if family members might be at risk for inherited mutations.

What Comes Next

The study authors acknowledged several limitations in their work. Researchers have not yet established how intermediate tumor cells impact overall survival or how they react to standard chemotherapy regimes, Fox News reported.

To fully understand when these cellular variations arise, researchers plan to evaluate pancreatic tissue from individuals without cancer. Steele and her team, who initiated the research at Henry Ford Health before continuing at UC, emphasized that larger studies with broader patient cohorts are necessary before these insights can be translated into targeted clinical therapies.

The research received funding support in part from the National Cancer Institute.